博雅生物获得破伤风人免疫球蛋白药品注册证书

Core Viewpoint - Boya Bio's recent announcement highlights the receipt of a drug registration certificate for Tetanus Human Immunoglobulin from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1 - The drug registration certificate has the standard number YBS00762025, confirming the product's compliance with regulatory standards [1] - The formulation of the drug is an injectable solution, with each vial containing 250 IU of tetanus antibodies in a volume of 2.5 ml [1]